These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18280251)

  • 1. A new T677C mutation of the aspartoacylase gene encodes for a protein with no enzymatic activity.
    Di Pietro V; Gambacurta A; Amorini AM; Finocchiaro A; D'Urso S; Ceccarelli L; Tavazzi B; Giardina B; Lazzarino G
    Clin Biochem; 2008 May; 41(7-8):611-5. PubMed ID: 18280251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.
    Herga S; Berrin JG; Perrier J; Puigserver A; Giardina T
    FEBS Lett; 2006 Oct; 580(25):5899-904. PubMed ID: 17027983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.
    Velinov M; Zellers N; Styles J; Wisniewski K
    Clin Genet; 2008 Mar; 73(3):288-9. PubMed ID: 18070137
    [No Abstract]   [Full Text] [Related]  

  • 4. A benign polymorphism in the aspartoacylase gene may cause misinterpretation of Canavan gene testing.
    Propheta O; Magal N; Shohat M; Eyal N; Navot N; Horowitz M
    Eur J Hum Genet; 1998; 6(6):635-7. PubMed ID: 9887384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.
    Kaul R; Gao GP; Balamurugan K; Matalon R
    Nat Genet; 1993 Oct; 5(2):118-23. PubMed ID: 8252036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analysis of aspartoacylase: implications for Canavan disease.
    Hershfield JR; Pattabiraman N; Madhavarao CN; Namboodiri MA
    Brain Res; 2007 May; 1148():1-14. PubMed ID: 17391648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel splice site mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Rady PL; Penzien JM; Vargas T; Tyring SK; Matalon R
    Eur J Paediatr Neurol; 2000; 4(1):27-30. PubMed ID: 10701101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
    Unalp A; Altiok E; Uran N; Oztürk A; Yüksel S
    J Trop Pediatr; 2008 Jun; 54(3):208-10. PubMed ID: 17999961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
    Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
    Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel aspartoacylase (ASPA) gene mutation in Canavan disease.
    Durmaz AA; Akin H; Onay H; Vahabi A; Ozkinay F
    Fetal Pediatr Pathol; 2012 Aug; 31(4):236-9. PubMed ID: 22468686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and preliminary characterization of brain aspartoacylase.
    Moore RA; Le Coq J; Faehnle CR; Viola RE
    Arch Biochem Biophys; 2003 May; 413(1):1-8. PubMed ID: 12706335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canavan disease: diagnosis and molecular analysis.
    Matalon R
    Genet Test; 1997; 1(1):21-5. PubMed ID: 10464621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease.
    Tacke U; Olbrich H; Sass JO; Fekete A; Horvath J; Ziyeh S; Kleijer WJ; Rolland MO; Fisher S; Payne S; Vargiami E; Zafeiriou DI; Omran H
    Neuropediatrics; 2005 Aug; 36(4):252-5. PubMed ID: 16138249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartoacylase gene knockout in the mouse: impact on reproduction.
    Surendran S; Szucs S; Tyring SK; Matalon R
    Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
    Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
    Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canavan disease: a novel mutation.
    Schober H; Luetschg J; Hoeliner I; Kalb S; Simma B
    Pediatr Neurol; 2011 Oct; 45(4):256-8. PubMed ID: 21907889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of the aspartoacylase gene in non-Jewish patients with Canavan disease.
    Zeng BJ; Pastores GM; Leone P; Raghavan S; Wang ZH; Ribeiro LA; Torres P; Ong E; Kolodny EH
    Adv Exp Med Biol; 2006; 576():165-73; discussion 361-3. PubMed ID: 16802711
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in Canavan disease.
    Matalon R; Michals-Matalon K
    Adv Pediatr; 1999; 46():493-506. PubMed ID: 10645473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliable prenatal diagnosis of Canavan disease by measuring N-acetylaspartate in amniotic fluid using liquid chromatography tandem mass spectrometry.
    Al-Dirbashi OY; Kurdi W; Imtiaz F; Ahmad AM; Al-Sayed M; Tulbah M; Al-Nemer M; Rashed MS
    Prenat Diagn; 2009 May; 29(5):477-80. PubMed ID: 19235826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reexamination of aspartoacylase: is this human enzyme really a glycoprotein?
    Wang Q; Viola RE
    Arch Biochem Biophys; 2014 Apr; 548():66-73. PubMed ID: 24632142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.